IRIS
DAMIANO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 977
EU - Europa 536
AS - Asia 272
AF - Africa 18
SA - Sud America 3
Totale 1.806
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 950
IT - Italia 165
SG - Singapore 160
UA - Ucraina 118
CN - Cina 100
NL - Olanda 63
FI - Finlandia 45
IE - Irlanda 44
DE - Germania 39
CA - Canada 26
SE - Svezia 23
CI - Costa d'Avorio 18
GB - Regno Unito 16
FR - Francia 13
IN - India 9
AR - Argentina 2
BE - Belgio 2
CZ - Repubblica Ceca 2
ES - Italia 2
HK - Hong Kong 2
PT - Portogallo 2
CH - Svizzera 1
EC - Ecuador 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
Totale 1.806
Salva come PNG Salva come JPEG
Città #
Chandler 166
Singapore 129
Jacksonville 126
Amsterdam 62
Millbury 61
Santa Clara 48
Ashburn 45
Woodbridge 44
Princeton 41
Naples 35
Beijing 29
Ottawa 26
Nanjing 24
Wilmington 22
San Giovanni Rotondo 19
Napoli 17
Boston 12
Nanchang 10
Norwalk 10
Houston 9
Milan 9
Shenyang 9
Boardman 8
Des Moines 6
Changsha 4
Hebei 4
Hicksville 4
Kronberg 4
Palma Campania 4
Andrano 3
Caserta 3
Florence 3
Lawrence 3
Malappuram 3
Pomigliano d'Arco 3
Tianjin 3
Villaricca 3
Albacete 2
Alges 2
Aversa 2
Cerro al Lambro 2
Cipolletti 2
Courcelles 2
Dublin 2
Falls Church 2
Grumo Nevano 2
Hong Kong 2
Indiana 2
Jiaxing 2
Kochi 2
Leawood 2
Los Angeles 2
Osimo 2
Pune 2
Salerno 2
San Mateo 2
Seattle 2
Shanghai 2
Villarosa 2
Washington 2
Yellow Springs 2
Arezzo 1
Berlin 1
Bologna 1
Carinola 1
Changchun 1
Dallas 1
Darmstadt 1
Formia 1
Frattamaggiore 1
Islington 1
Kunming 1
Lviv 1
Monmouth Junction 1
Mumbai 1
Munich 1
New Delhi 1
Ningbo 1
Oleggio 1
Ottaviano 1
Pisa 1
Redwood City 1
Slough 1
Springfield 1
Taizhou 1
Varedo 1
Walnut 1
Zurich 1
Totale 1.086
Salva come PNG Salva come JPEG
Nome #
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 52
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 52
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 51
Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report 51
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 50
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 50
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 50
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 48
Combination of biological therapies in non-small cell lung cancer. 47
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 47
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 47
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 46
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 45
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 44
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 44
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 44
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 43
Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: An observational retrospective-prospective analysis from real life 42
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 41
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 41
Type 2 Deiodinase Thr92Ala Polymorphism and Aging Are Associated with a Decreased Pituitary Sensitivity to Thyroid Hormone 40
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 40
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 39
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 39
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. 38
The mechanisms of resistance to EGFR inhibitors. 38
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. 37
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 36
Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity 36
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 36
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 35
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review 35
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 33
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 33
Imatinib mesylate in thymic epithelial malignancies. 32
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 31
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 30
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 27
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’) 27
The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene. 1997 Feb 27;14(8):923-8. 26
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. 26
Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors. 26
Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits. 24
Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia 23
The cAMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 23
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. 20
Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy 19
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. 19
Differential effects of type I and type II protein kinase A isoforms on chinese hamster ovary cell cycle and proliferation. 19
Tumori rari 14
Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics 12
Long term deficiency of vitamin D in germ cell testicular cancer survivors 10
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 9
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study 2
Totale 1.869
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.376
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.376
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020117 0 0 0 0 24 1 0 3 1 18 26 44
2020/2021227 0 23 29 24 25 33 25 0 30 5 33 0
2021/2022310 2 0 0 4 4 8 7 11 46 23 89 116
2022/2023404 48 40 13 20 41 52 0 31 62 67 23 7
2023/2024280 8 40 30 45 26 20 3 29 5 14 45 15
2024/2025235 70 93 4 8 60 0 0 0 0 0 0 0
Totale 1.869